Multichannel
Reimagining the life sciences beyond COVID-19
A new report from Reuters Events Pharma and EY reveals the impacts on the life sciences sector and analyses the road ahead
More Articles
Clinical
Automation is key in cell and gene therapy manufacturing
Although the list of cell and gene therapies is growing, prices remain high. Now developers are working on a road map to streamline production and drop costs
Multichannel
How sustainable is remote health at scale?
Remote health has proved its worth to the entire healthcare sector but sustaining and scaling it requires work from every stakeholder
Patients and Medical
Digital companions: helping improve patient treatment journeys
The virtual health explosion isn't going away. This just at the start of an era of digital enhancement
Patients and Medical
Racially diverse clinical trials: A new patient-led legacy takes root
Attempts to make trials more diverse aren’t working. To overcome far-reaching inequality and deep distrust, pharma must be educated by, as well as educate, under-served communities
Patients and Medical
Patient engagement: Breaking through in digital
The pandemic is serving as an accelerated lesson in the possibilities of digital engagement. Now pharma must work out how to harness its full potential
Commercial
Adapting to the multichannel imperative: A special report
Pharma’s gradual evolution into digital-first commercial has become urgent in the COVID-19 world. A comprehensive multi-channel approach including the use of digital tools to enhance customer engagement will transform pharma sales.
Multichannel
COVID-19: The tipping point for rapid tech adoption
A new pandemic-driven technological revolution is reshaping the entire healthcare system in 2020 and everyone’s sense of what is possible beyond it
Patients and Medical
Amplifying the patient voice in rare disease access
Rare disease patients are organising like never before, turning up the publicity volume and becoming ever more active in driving cures in the lab and even the boardroom
Patients and Medical
From complexity to clarity in cell and gene therapy
Breakthrough CGT therapies are coming thick and fast, now pharma must work on multiple fronts to educate non-specialist stakeholders about their exciting possibilities